Pediatric Neurology

The Path to Diagnosis: Ruling Out Look-Alikes

At a Glance

NESCAV syndrome is diagnosed by matching a child’s neurological features with a pathogenic or likely pathogenic KIF1A variant. Testing should include copy-number analysis when appropriate, and clinicians should rule out treatable conditions such as cerebral folate transport deficiency.

Finding an answer for a child’s neurological challenges is rarely a straight path. For many families, the journey to a NESCAV diagnosis involves a long “diagnostic odyssey” filled with multiple specialists, inconclusive tests, and the stress of not knowing ^[1]. Because the symptoms of NESCAV—such as low muscle tone, developmental delay, and vision issues—overlap with many other conditions, doctors must use advanced tools to find the correct answer.

The Role of Genetic Testing

Diagnosis relies on a compatible clinical picture plus identifying a pathogenic or likely pathogenic variant in the KIF1A gene ^[2]. Broad genetic sequencing is common, though targeted panels or chromosomal tests may also be used depending on the laboratory.

Whole Exome Sequencing (WES): This looks at the “protein-coding” parts of your child’s DNA and is often used to identify KIF1A variants ^[2].
Whole Genome Sequencing (WGS): This is an even broader test that looks at the entire DNA sequence. It can be particularly helpful if WES results are unclear or negative ^[3].
Copy-Number Variation (CNV) Analysis: Some tests only look for “spelling errors” in the DNA. However, some children are missing larger chunks of the KIF1A gene entirely ^[4]^[5]. It is critical to ensure testing includes a search for these deletions or duplications.

It is important to understand that a Variant of Uncertain Significance (VUS) should not be used by itself to establish or exclude a NESCAV diagnosis. If a VUS or negative result is found, periodic reinterpretation by a genetics team may be appropriate as scientific knowledge evolves. Furthermore, a negative result on one type of test does not completely rule out a KAND-spectrum disorder.

The KIF1A Spectrum: Which One Is It?

Not every KIF1A mutation leads to the NESCAV pattern. Doctors use the genetic results and clinical symptoms to place a child on the KAND spectrum ^[6].

NESCAV: A complex phenotype involving neurodegeneration, spasticity, and variable vision or cerebellar findings ^[7].
SPG30 (Spastic Paraplegia 30): This phenotype primarily affects the legs, causing stiffness and weakness. It can be “pure” (only legs) or “complicated” (with other symptoms) ^[8].
HSAN2 (Hereditary Sensory and Autonomic Neuropathy Type 2): A rare recessive form where main symptoms include a loss of pain sensation and autonomic issues ^[8].

Ruling Out the “Look-Alikes”

Because the symptoms can mimic other conditions, your medical team may perform a “differential diagnosis” to rule out other possibilities. This is especially vital for conditions that have specific treatments.

Condition	Why it looks like NESCAV	Key Difference
Cerebral Folate Transport Deficiency	Causes developmental delay, seizures, and movement problems ^[9].	Potentially Treatable: early specialist-directed treatment with folinic acid may improve outcomes. CSF testing (spinal tap) may be needed for diagnosis ^[10].
Isolated Sulfite Oxidase Deficiency (ISOD)	Causes seizures, abnormal muscle tone, and developmental delay ^[11].	Often presents neonatally and involves specific metabolic markers in fresh urine ^[11].
CLN11 (Neuronal Ceroid Lipofuscinosis 11)	Involves progressive vision loss, ataxia, and seizures ^[12].	Caused by variants in the GRN gene, not KIF1A ^[13].

Why Treatable Mimics Come First

A hallmark of good neurological care is ruling out the “treatable mimics.” For example, with Cerebral Folate Transport Deficiency, early diagnosis and treatment with high-dose folinic acid may significantly improve some features, though full recovery is not guaranteed ^[10]^[14].

If your child has a VUS on their KIF1A report, doctors may run metabolic tests to ensure they aren’t missing a condition that could be treated immediately ^[15]^[9]. Identifying NESCAV isn’t just about finding a name; it’s about ensuring every other possible avenue for treatment has been properly evaluated.

Common questions in this guide

How is NESCAV syndrome diagnosed?

Doctors look for a clinical pattern that fits NESCAV and a pathogenic or likely pathogenic change in the KIF1A gene. Testing may include whole exome sequencing, whole genome sequencing, targeted panels, and copy-number analysis, depending on the laboratory and the child’s results.

What does a VUS or negative KIF1A test mean for my child?

A variant of uncertain significance, or VUS, cannot by itself confirm or rule out NESCAV. A negative result on one testing method also may not exclude a KIF1A-related disorder, so a genetics team may review the result again as knowledge changes or consider broader testing.

Why does KIF1A testing need copy-number analysis?

Some tests detect small DNA spelling changes but may miss larger deletions or duplications involving the KIF1A gene. Copy-number analysis checks for these missing or extra DNA segments and can help when a child’s symptoms strongly suggest a KIF1A-related disorder.

Which treatable conditions can resemble NESCAV syndrome?

Cerebral folate transport deficiency, isolated sulfite oxidase deficiency, and CLN11 can share features such as developmental delay, seizures, movement problems, vision loss, or abnormal muscle tone. Doctors may use blood, urine, spinal-fluid, or genetic testing to look for these conditions; cerebral folate transport deficiency may respond to specialist-directed folinic acid.

How are NESCAV, SPG30, and HSAN2 different?

They are different patterns within the KIF1A-related disorder spectrum. NESCAV may involve neurodegeneration, spasticity, and variable vision or cerebellar findings; SPG30 mainly affects the legs with stiffness and weakness; HSAN2 is associated with loss of pain sensation and autonomic problems.

When might whole genome sequencing be considered for suspected NESCAV?

Whole genome sequencing examines the entire DNA sequence and may be considered when whole exome sequencing is unclear or negative. It provides a broader search, while the genetics team decides whether it fits the child’s clinical picture and previous test results.

Get notified when new evidence is published on NESCAV syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (15)

1
"I felt like a lone ranger": experiences of Australian families living with KIF1A-Associated Neurological Disorder.
Miwa-Dale K, Norman K, Dawson-McClaren B, et al.
Journal of community genetics 2026; (17(3)).
PMID: 42252374
2
Autosomal dominant neurodevelopmental disorders associated with KIF1A gene variants in 6 pediatric patients.
Lin J, Li N, Yao R, et al.
Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 2023; (52(6)):693-700 doi:10.3724/zdxbyxb-2023-0457.
PMID: 38105687
3
A Novel De Novo Missense Mutation in KIF1A Associated with Young-Onset Upper-Limb Amyotrophic Lateral Sclerosis.
Bernard E, Cluse F, Bohic A, et al.
International journal of molecular sciences 2024; (25(15)) doi:10.3390/ijms25158170.
PMID: 39125740
4
Monoallelic KIF1A-related disorders: a multicenter cross sectional study and systematic literature review.
Vecchia SD, Tessa A, Dosi C, et al.
Journal of neurology 2022; (269(1)):437-450 doi:10.1007/s00415-021-10792-3.
PMID: 34487232
5
Understanding speech and language in KIF1A-associated neurological disorder.
Morison LD, Vogel AP, Christodoulou J, et al.
European journal of human genetics : EJHG 2026; (34(1)):78-89 doi:10.1038/s41431-025-01867-0.
PMID: 40379967
6
KIF1A-Associated Neurological Disorder (KAND): Spectrum of Movement and Motor Disorders in a Cohort of 51 Patients.
Bernardi K, Ribeiro G, Battaglia N, et al.
Movement disorders : official journal of the Movement Disorder Society 2026; (41(10)):2737-2744 doi:10.1002/mds.70420.
PMID: 42500835
7
The Novel KIF1A Missense Variant (R169T) Strongly Reduces Microtubule Stimulated ATPase Activity and Is Associated With NESCAV Syndrome.
Aguilera C, Hümmer S, Masanas M, et al.
Frontiers in neuroscience 2021; (15()):618098 doi:10.3389/fnins.2021.618098.
PMID: 34121983
8
Variants in KIF1A gene in dominant and sporadic forms of hereditary spastic paraparesis.
Citterio A, Arnoldi A, Panzeri E, et al.
Journal of neurology 2015; (262(12)):2684-90 doi:10.1007/s00415-015-7899-9.
PMID: 26410750
9
Late diagnosis of cerebral folate deficiency: Fewer seizures with folinic acid in adult siblings.
Ferreira P, Luco SM, Sawyer SL, et al.
Neurology. Genetics 2016; (2(1)):e38 doi:10.1212/NXG.0000000000000038.
PMID: 27066576
10
Hypomyelination caused by a novel homozygous pathogenic variant in FOLR1: complete clinical and radiological recovery with oral folinic acid therapy and review of the literature.
Potic A, Perrier S, Radovic T, et al.
Orphanet journal of rare diseases 2023; (18(1)):187 doi:10.1186/s13023-023-02802-6.
PMID: 37443037
11
Isolated sulfite oxidase deficiency.
Claerhout H, Witters P, Régal L, et al.
Journal of inherited metabolic disease 2018; (41(1)):101-108 doi:10.1007/s10545-017-0089-4.
PMID: 28980090
12
Further description of the phenotypic spectrum of neuronal ceroid lipofuscinosis type 11.
Nóbrega PR, Paiva ARB, Amorim Junior AD, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2025; (27(1)):101291 doi:10.1016/j.gim.2024.101291.
PMID: 39394881
13
Homozygous GRN mutations: new phenotypes and new insights into pathological and molecular mechanisms.
Huin V, Barbier M, Bottani A, et al.
Brain : a journal of neurology 2020; (143(1)):303-319 doi:10.1093/brain/awz377.
PMID: 31855245
14
Cerebral folate transporter deficiency syndrome in three siblings: Why genetic testing for developmental and epileptic encephalopathies should be performed early and include the FOLR1 gene.
Brunetti S, Malerba L, Giordano L, et al.
American journal of medical genetics. Part A 2021; (185(8)):2526-2531 doi:10.1002/ajmg.a.62345.
PMID: 34008900
15
Genotype-phenotype correlations in 18 European patients with heterozygous KIF1A variants: key considerations for assessing KIF1A variant causality.
Uhrova Meszarosova A, Galiart E, Lassuthova P, et al.
Frontiers in medicine 2025; (12()):1704209 doi:10.3389/fmed.2025.1704209.
PMID: 41585230

This page explains how clinicians evaluate NESCAV syndrome and similar conditions for informational purposes only and does not constitute medical advice. A pediatric neurologist and genetics team should interpret your child’s results and guide testing decisions.